256 related articles for article (PubMed ID: 1673980)
1. Generation of lymphokine-activated killer activity in T cells. Possible regulatory circuits.
Geller RL; Smyth MJ; Strobl SL; Bach FH; Ruscetti FW; Longo DL; Ochoa AC
J Immunol; 1991 May; 146(10):3280-8. PubMed ID: 1673980
[TBL] [Abstract][Full Text] [Related]
2. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC
J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481
[TBL] [Abstract][Full Text] [Related]
3. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic killing of CD4+ T lymphocytes in HIV-1-infected PHA-stimulated PBL cultures is mediated by CD8+ LAK cells.
Wang L; Klimpel GR; Planas JM; Li H; Cloyd MW
Virology; 1998 Feb; 241(2):169-80. PubMed ID: 9499792
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
6. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
7. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
8. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
9. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
Lynch DH; Miller RE
J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
[TBL] [Abstract][Full Text] [Related]
10. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
Atzpodien J; Gulati SC
Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
[TBL] [Abstract][Full Text] [Related]
11. IL-4 inhibits IL-2-mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures.
Spits H; Yssel H; Paliard X; Kastelein R; Figdor C; de Vries JE
J Immunol; 1988 Jul; 141(1):29-36. PubMed ID: 2454260
[TBL] [Abstract][Full Text] [Related]
12. Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells.
Kasid A; Bell GI; Director EP
J Immunol; 1988 Jul; 141(2):690-8. PubMed ID: 3133414
[TBL] [Abstract][Full Text] [Related]
13. Sequential TNF and TGF-beta regulation of expansion and induction of cytotoxicity in long-term cultures of lymphokine-activated killer cells.
Koberda J; Przepiorka D; Moser RP; Grimm EE
Lymphokine Cytokine Res; 1994 Apr; 13(2):139-45. PubMed ID: 8061115
[TBL] [Abstract][Full Text] [Related]
14. Modulation of lymphokine release and cytolytic activities by activating peripheral blood lymphocytes via CD2.
Valentin H; Groux H; Gelin C; Chretien I; Bernard A
J Immunol; 1990 Feb; 144(3):875-82. PubMed ID: 1967277
[TBL] [Abstract][Full Text] [Related]
15. Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.
Baxevanis CN; Voutsas IF; Soler MH; Gritzapis AD; Tsitsilonis OE; Stoeva S; Voelter W; Arsenis P; Papamichail M
Immunopharmacol Immunotoxicol; 1998 Aug; 20(3):355-72. PubMed ID: 9736441
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
17. Regulation of lymphokine-activated killer activity in T-replete and T-cell-depleted human bone marrow by interleukin 4.
Drobyski WR; LeFever AV; Truitt RL
Exp Hematol; 1991 Oct; 19(9):950-7. PubMed ID: 1716592
[TBL] [Abstract][Full Text] [Related]
18. TGF-beta mediates natural suppressor activity of IL-2-activated lymphocytes.
Yamamoto H; Hirayama M; Genyea C; Kaplan J
J Immunol; 1994 Apr; 152(8):3842-7. PubMed ID: 8144953
[TBL] [Abstract][Full Text] [Related]
19. Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset.
Ballas ZK; Rasmussen W
J Immunol; 1993 Jan; 150(1):17-30. PubMed ID: 7678028
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
